Jun 7, 2026 02:30PM
Jun 7, 2026 02:30PM
May 7, 2026 01:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with
Feb 19, 2026 01:00AM
Aug 14, 2025 01:00AM
Jun 2, 2025 01:00AM
May 19, 2025 09:00AM
Feb 20, 2025 04:08AM
Feb 20, 2025 01:00AM
Dec 19, 2024 02:59PM Zealand Pharma (ZEAL) Receives FDA CRL for the glepaglutide New Drug Application
Dec 19, 2024 02:58PM
Nov 7, 2024 01:00AM
Oct 8, 2024 07:00PM
Oct 8, 2024 06:45PM
Oct 8, 2024 02:40AM
Aug 15, 2024 01:00AM
Jun 7, 2024 04:38AM Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Jun 6, 2024 06:29AM
Jun 6, 2024 06:29AM
May 31, 2024 10:03AM
May 31, 2024 10:03AM
May 16, 2024 01:00AM
Feb 27, 2024 01:00AM
Feb 26, 2024 02:06AM Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibro
Dec 26, 2023 04:03AM
Dec 23, 2023 04:47AM
Dec 22, 2023 04:30AM
Nov 9, 2023 01:00AM
Oct 5, 2023 05:53AM
Aug 30, 2023 01:33AM
Aug 17, 2023 01:00AM Zealand Pharma Announces Financial Results for the First Half of 2023
Jun 30, 2023 01:34PM
Jun 30, 2023 01:32PM
Jun 23, 2023 05:15PM
May 11, 2023 01:00AM
May 10, 2023 02:30AM
Mar 2, 2023 04:30AM
Mar 2, 2023 04:30AM Correction: Zealand Pharma Announces Full Year Results for 2022
Mar 2, 2023 01:00AM
Mar 2, 2023 01:00AM
Nov 10, 2022 09:00AM
Nov 10, 2022 09:00AM
Sep 30, 2022 06:22AM
Sep 30, 2022 06:15AM
Sep 30, 2022 06:15AM Zealand Pharma Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (EASE 1)
Sep 19, 2022 02:00AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All